Last reviewed · How we verify
Neuromuscular Blocking Agents and reversing agents
Neuromuscular Blocking Agents and their reversing agents, marketed by Universitaire Ziekenhuizen KU Leuven, hold a significant position in the anesthesia and surgical care market. A key strength is the protection of their core composition patent, which is set to expire in 2028, providing a strong barrier to generic competition. The primary risk is the potential for increased competition as the patent expiration approaches, which could erode market share and revenue.
At a glance
| Generic name | Neuromuscular Blocking Agents and reversing agents |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach (PHASE4)
- Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: